Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-144-3p
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
ARID1A
Cancer name
Renal Cell Carcinoma
Cancer site
Kidney
Treatment type
Chemotherapy
Drug
Sunitinib
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Up
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
Higher miR-144-3p may enhance malignancy and resistance to Sunitinib in ccRCC by targeting ARID1A, the observations may uncover novel strategies of ccRCC treatment.
Tissue resource
renal cell carcinoma tumor tissues
human renal cell carcinoma cell lines 786-O
human renal cell carcinoma cell lines SN12-PM6
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Union hospital, Tongji Medical College
American Type Culture Collection
MD Anderson Cancer Center
Country
China
USA
Continent
Asia
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.